$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How much does a box of the ROS1 mutated lung cancer targeting drug lorlatinib cost? Where to buy?
2025-10-19 11:44:20
Check Details
New treatment for non-small cell lung cancer: targeted drug lorlatinib
2025-10-19 11:44:20
Check Details
Effectiveness data of lorlatinib in first-line treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Efficacy and safety of lorlatinib in the treatment of newly diagnosed ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Xalkori (crizotinib) can be used for ALK-positive locally advanced or metastatic non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Efficacy and safety of Xacori in the treatment of ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
How long will it take for patients with lung cancer to develop resistance to Xalkori (crizotinib)?
2025-10-19 11:44:20
Check Details
Xalkori (crizotinib) has significant anti-cancer effects on ROS1-rearranged advanced non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Study of Crizotinib (Xalkori) in Patients with EGFR Mutated Non-Small Cell Lung Cancer
2025-10-19 11:44:20
Check Details
FDA Grants Xalkori (Crizotinib) Breakthrough Drug Designation
2025-10-19 11:44:20
Check Details
Has the lung cancer targeted drug Xalkore (crizotinib) been included in the national medical insurance in China?
2025-10-19 11:44:20
Check Details
Contraindications and precautions for patients with lung cancer taking Xalkore (crizotinib)
2025-10-19 11:44:20
Check Details
1
2
...
9971
9972
9973
9974
9975
9976
9977
...
10234
10235
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
2
Elagolix GnRH Antagonist for Endometriosis Pain: Mechanism, Dosing, Bone and Mood Safety
3
Diazoxide Oral Suspension Inadequate Response: Glucose-Based Titration, Stop at 2–3 Weeks, Re-evaluate Hypoglycemia Cause
4
Ambrisentan Adjunct for IgA Nephropathy Proteinuria: ETA Mechanism, Real-World Evidence, Safety Monitoring
5
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
6
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
7
Lemborexant for Insomnia: Dual Orexin 5/10mg, 7-Hour Bedtime, 7–10-Day Review and Safety
8
Fayuvi (rebisufligene etisparvovec-hopf) for MPS IIIA: AAV9 Single Infusion, Weight-Based Dose, Steroids, Liver/Platelet Monitoring
9
Trelagliptin Once-Weekly DPP-4 for Type 2 Diabetes: Dosing, Renal Adjustment, Discontinuation
10
Orforglipron (Foundayo) vs Metformin: Oral GLP-1 Weight Loss and T2D Use
11
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
12
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS